Business Context and Reporting Period
Verastem, Inc. filed this Form 8-K on April 23, 2019, to report the entry into a material definitive agreement. The Company, incorporated in Delaware, is a biopharmaceutical company focused on developing novel therapies for cancer.
Key Financial Metrics and Debt Structure
The filing details a Fourth Amendment to the Loan and Security Agreement with Hercules Capital, Inc. Key terms include:
- Total Borrowing Capacity: Up to $75.0 million.
- Outstanding Principal (as of Amendment Date): $35.0 million, comprising $25.0 million converted from the original agreement and a new $10.0 million draw.
- Remaining Capacity: $40.0 million available in future tranches.
- Interest Rate: Floating rate equal to the greater of 9.75% or a formula based on the prime rate (capped at 12.00%).
- Maturity Date: December 1, 2022.
- Repayment Terms: Interest-only payments until April 1, 2021 (extendable to December 1, 2021 subject to revenue milestones), followed by monthly amortization.
- Collateral: Lien on substantially all assets, excluding intellectual property.
Material Changes and Covenants
The amendment restructures the existing debt and introduces performance-based borrowing tranches:
- 2019 Term B Loan: Up to $15.0 million available upon generating cumulative net product revenues of $37.5 million by April 30, 2020, or $50.0 million by June 30, 2020.
- 2019 Term C Loan: Up to $25.0 million available through December 31, 2021, subject to lender approval.
- Covenants: Includes liquidity, minimum net revenue, and financial reporting covenants, along with limitations on dividends, indebtedness, and corporate changes.
- Fees: A final payment fee of 4.5% ($1.125 million) was due on the outstanding principal of $25.0 million immediately prior to the amendment. No prepayment charges were incurred.
Outlook, Risks, and Management Commentary
The Company issued a press release on April 23, 2019, announcing the amendment. The filing does not provide specific forward-looking guidance on revenue or profit margins beyond the revenue milestones required to unlock additional loan tranches. The primary risk highlighted is the Company's ability to meet the revenue covenants to access future funding tranches and maintain compliance with the liquidity and minimum net revenue covenants.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service interest-only payments until 2021.
- Assess the likelihood of achieving the $37.5 million or $50.0 million cumulative net product revenue milestones to unlock the $15.0 million Term B Loan.
- Review the impact of the 4.5% final payment fee on the Company's immediate cash flow.
- Monitor compliance with the minimum net revenue covenant to avoid an event of default.
- Confirm the status of the $25.0 million Term C Loan availability conditions.